Literature DB >> 9749586

A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease.

N A Tatton1, A Maclean-Fraser, W G Tatton, D P Perl, C W Olanow.   

Abstract

In situ end-labeling (ISEL) has become a widely used method to determine whether cells die via apoptosis by detecting double-stranded DNA breaks that are the result of endonuclease digestion. The enzyme terminal deoxynucleotidyl transferase can be used to label the digested 3'-OH ends of DNA with biotin-, digoxigenin-, or fluorescent probe-conjugated nucleotides. However, both single-stranded and double-stranded DNA breaks can be labeled by this method and therefore ISEL cannot unequivocally demonstrate apoptosis when used alone. We have developed a fluorescent double-labeling method using ISEL combined with the cyanine dye YOYO-1 that binds to DNA. When combined with confocal laser microscopy and deconvolution analysis, YOYO-1 can demonstrate the presence or absence of nuclear chromatin condensation and thus confirm that ISEL-positive nuclei are indeed apoptotic. Preliminary findings indicate that dopaminergic neurons in the substantia nigra compacta die via apoptosis in Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9749586     DOI: 10.1002/ana.410440721

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  34 in total

1.  Caspase-mediated degradation of AMPA receptor subunits: a mechanism for preventing excitotoxic necrosis and ensuring apoptosis.

Authors:  G W Glazner; S L Chan; C Lu; M P Mattson
Journal:  J Neurosci       Date:  2000-05-15       Impact factor: 6.167

2.  Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease.

Authors:  A Hartmann; S Hunot; P P Michel; M P Muriel; S Vyas; B A Faucheux; A Mouatt-Prigent; H Turmel; A Srinivasan; M Ruberg; G I Evan; Y Agid; E C Hirsch
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

3.  Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease.

Authors:  V Viswanath; Y Wu; R Boonplueang; S Chen; F F Stevenson; F Yantiri; L Yang; M F Beal; J K Andersen
Journal:  J Neurosci       Date:  2001-12-15       Impact factor: 6.167

4.  Experimental strategy to identify genes susceptible to oxidative stress in nigral dopaminergic neurons.

Authors:  Myung S Yoo; Hibiki Kawamata; Dae J Kim; Hong S Chun; Jin H Son
Journal:  Neurochem Res       Date:  2004-06       Impact factor: 3.996

5.  Chronic deprivation of TrkB signaling leads to selective late-onset nigrostriatal dopaminergic degeneration.

Authors:  Maryna Baydyuk; Madeline T Nguyen; Baoji Xu
Journal:  Exp Neurol       Date:  2010-12-28       Impact factor: 5.330

6.  Neuroprotective and neurorestorative strategies for neuronal injury.

Authors:  M F Beal; T Palomo; R M Kostrzewa; T Archer
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

7.  Review of apoptosis vs. necrosis of substantia nigra pars compacta in Parkinson's disease.

Authors:  R M Kostrzewa
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

8.  Mitochondrial permeability transition pore regulates Parkinson's disease development in mutant α-synuclein transgenic mice.

Authors:  Lee J Martin; Samantha Semenkow; Allison Hanaford; Margaret Wong
Journal:  Neurobiol Aging       Date:  2013-11-16       Impact factor: 4.673

9.  An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage.

Authors:  Todd B Sherer; Ranjita Betarbet; Amy K Stout; Serena Lund; Melisa Baptista; Alexander V Panov; Mark R Cookson; J Timothy Greenamyre
Journal:  J Neurosci       Date:  2002-08-15       Impact factor: 6.167

Review 10.  Programmed cell death in Parkinson's disease.

Authors:  Katerina Venderova; David S Park
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.